Comparison

BPC-157 vs TB-500

Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research

BPC-157

Also: Body Protection Compound-157, Pentadecapeptide BPC 157

Preclinical

A synthetic peptide derived from a protein found in human gastric juice. Known for its remarkable tissue healing properties across multiple body systems. FDA classified as Category 2 in 2023, restricting compounding.

HealingAnimal Studies
Preclinical

A synthetic 17-amino acid fragment of Thymosin Beta-4 (TB-4). Unlike TB-4, TB-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. Note: Many vendors mislabel TB-4 as 'TB-500' in premixed products.

HealingAnimal Studies

Key Comparison Insights

  • Both peptides belong to the Healing category, suggesting similar primary applications.
  • These peptides are often used together in healing protocols for synergistic effects.

Detailed Comparison

AttributeBPC-157TB-500
CategoryHealingHealing
FDA StatusNot FDA ApprovedNot FDA Approved
Clinical Status
Pre
I
II
III
IV
FDA
Pre
I
II
III
IV
FDA
Mechanism of ActionBPC-157 modulates the nitric oxide system, promotes angiogenesis (new blood vessel formation), and upregulates growth hormone receptors. It also interacts with the dopaminergic system and has been shown to accelerate tendon-to-bone healing by promoting collagen synthesis.TB-500 is derived from the active region of the full Thymosin Beta-4 protein. It promotes cell migration by binding to and sequestering actin, a protein essential for cell movement. It upregulates actin expression, promotes angiogenesis, reduces inflammation, and facilitates hair follicle stem cell migration for wound healing.
Common Dosing
250-500 mcg twice daily
1-2x daily
2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance)
2x weekly for 4-6 weeks, then 1x weekly
AdministrationSubcutaneous injection near injury site, or systemicSubcutaneous or intramuscular injection
Typical Duration4-12 weeks in most research protocols4-6 weeks loading, then maintenance
Best Time to TakeMorning and evening (or near injury site timing)Morning or evening
Possible Side Effects
May vary by individual
  • Generally well-tolerated in preclinical studies
  • Nausea
  • Dizziness
  • Injection site reactions
  • Fatigue
  • +4 more
  • Generally well-tolerated in preclinical studies
  • Injection site reactions
  • Headache
  • Fatigue
  • Nausea
  • +5 more
Research SummaryExtensive preclinical studies demonstrate efficacy in healing tendons, ligaments, muscles, and the GI tract. 2025 AJSM systematic review: Of 544 articles screened, only 1 clinical study met inclusion criteria (rest were animal studies). Only 3 small human pilot studies exist (fewer than 30 total subjects). No pharmaceutical company has initiated FDA trials due to lack of patentability. FDA placed BPC-157 in Category 2 in September 2023.Animal studies show significant wound healing acceleration, cardiac tissue repair, and anti-inflammatory effects. Note: Phase 2 human trials exist for full Thymosin Beta-4 protein (not TB-500 specifically) - 73-patient venous stasis ulcer trial showed ~25% achieved complete healing at 3 months. Ophthalmologic trials for dry eye also completed. However, TB-500 fragment itself has no human clinical trials. FDA restricted TB-500 from compounding under Category 2. WADA prohibited at all times.

Frequently Asked Questions: BPC-157 vs TB-500

What is the difference between BPC-157 and TB-500?

BPC-157 is a healing peptide that a synthetic peptide derived from a protein found in human gastric juice. known for its remarkable tissue healing properties across multiple body systems. fda classified as category 2 in 2023, restricting compounding. TB-500 is a healing peptide that a synthetic 17-amino acid fragment of thymosin beta-4 (tb-4). unlike tb-4, tb-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. note: many vendors mislabel tb-4 as 'tb-500' in premixed products. The main differences lie in their mechanisms of action and clinical applications.

Which is better, BPC-157 or TB-500?

Neither is universally "better" - the choice depends on your specific goals. BPC-157 is typically used for healing purposes, while TB-500 is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.

Can BPC-157 and TB-500 be used together?

Some peptide protocols combine multiple compounds for synergistic effects. However, using BPC-157 and TB-500 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.

Related Comparisons

View Full Peptide Profiles